RNS Number : 7160K
Ondine Biomedical Inc.
30 August 2023
 

30 August 2023

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine" or the "Company")

 

Notice of Results and Investor Presentation via Investor Meet Company

 

Ondine Biomedical Inc. (LON: OBI) confirms it will be announcing its interim results for the six months ended 30 June 2023 on Monday, 25 September 2023.

Dr. Nicolas Loebel, Ondine's CTO and President, will provide a live presentation relating to the Interim Results via Investor Meet Company on 25 September 2023 at 4:30pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Ondine Biomedical Inc. via:

https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor

Investors who already follow Ondine Biomedical Inc. on the Investor Meet Company platform will automatically be invited.

 

Ondine Biomedical Inc.       

 

Carolyn Cross, CEO 

+001 (604) 665 0555

 

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

 

Aubrey Powell, Asha Chotai, Sam Butcher

+44 (0)20 7496 3000

 

 

RBC Capital Markets (Joint Broker)

 

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000


 

Vane Percy & Roberts (Media Contact)


Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORPLMFTMTATBMJ